Keeping Track of the Most Recent Treatment Updates
There are a lot of treatment updates for various malignancies happening seemingly all at once. We had the chance to speak with Laura S. Wood, RN, MSN, OCN, for her take on why these updates are coming so rapidly.
At the 3rd Annual School of Nursing Oncology, Oncology Nursing News® had the chance to sit down with Laura S. Wood, RN, MSN, OCN, renal cancer research coordinator at the Cleveland Clinic Taussig Cancer Center and one of the co-chairs of the School of Oncology Nursing, and discuss why she believes there are currently so many updates for various malignancies and where these updates are going.
TRANSCRIPTION
So, we're seeing quite a few updates in the treatment options for a variety of malignancies. That really goes back to better understanding the pathobiology of various cancers and understanding the role of the immune system and being able to target, and or reactivate, the immune system and recognizing that that plays a role in all different malignancies. And so, the clinical trial data has really matured and enrollment in clinical trials has increased our ability to answer those questions and identify those treatment options that are appropriate and those that are not appropriate for FDA approval and treatment.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
